SlidesetViral Hepatitis and Liver DiseaseIs Therapy-Induced HBs Decline the Same as Naturally Low HBs? - Jordan FeldView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhat to Watch Preclinical Therapeutics with Novel Mechanisms of Action - Massimo LevreroView Slideset
SlidesetViral Hepatitis and Liver DiseaseToxicity Profiles of Checkpoint Inhibition, What to Expect and When to Be Concerned - Morven CunninghamView Slideset
SlidesetViral Hepatitis and Liver DiseaseTherapy Induced Flares Associated With HBsAg Decline - Man-Fung YuenView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhy We Should Be Careful Using NA Withdrawal as a Therapeutic Option - Pietro LamperticoView Slideset
SlidesetViral Hepatitis and Liver DiseaseHBV-Specific T Cell Profile Associated with Functional Cure - Georg LauerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHow HBV RNA and HBcrAg Relate to cccDNA Transcriptional Activity - Barbara TestoniView Slideset
SlidesetViral Hepatitis and Liver DiseaseCam-N Jnj-6379. Lessons Learned From Reef-1 and -2 Studies - Michael BiermerView Slideset
SlidesetViral Hepatitis and Liver DiseaseEvidence of T Cell Restoration after siRNA Therapy - Emily ThiView Slideset
SlidesetViral Hepatitis and Liver DiseaseDevelopment of Assembly Next Generation Core Inhibitors - Grace WangView Slideset
SlidesetViral Hepatitis and Liver DiseaseBulevirtide - Data from Real World Usage after Approval in Europe - John FlahertyView Slideset
